Usmani, Saad Z. http://orcid.org/0000-0002-5484-8731
Karanes, Chatchada
Bensinger, William I.
D’Souza, Anita http://orcid.org/0000-0002-1092-5643
Raje, Noopur
Tuchman, Sascha A. http://orcid.org/0000-0003-2109-1573
Sborov, Douglas
Laubach, Jacob P. http://orcid.org/0000-0001-7565-2052
Bianchi, Giada http://orcid.org/0000-0003-3673-0104
Kanagavel, Dheepak
Saleem, Rao
Dubin, Franck
Campana, Frank
Richardson, Paul G. http://orcid.org/0000-0002-7426-8865
Article History
Received: 27 October 2020
Revised: 8 April 2021
Accepted: 26 April 2021
First Online: 28 May 2021
Compliance with ethical standards
:
: SZU: Research funding from Amgen, Array, BioPharma, Bristol Myers Squibb, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda; Consulting fees from Amgen, Bristol Myers Squibb, Celgene, GSK, Janssen, Merck, Sanofi, SkylineDX, and Takeda; Speaking fees from Amgen, Celgene, Janssen, and Takeda. CK: Nothing to disclose. WIB: Grant funding from Amgen, Bristol Myers Squibb, Janssen, and Sanofi; Personal fees from Amgen, Bristol Myers Squibb, Janssen, and Takeda. ADS: Research funding from Merck, Mundipharma EDO, Prothena, Sanofi, Takeda, and TeneoBio; Consulting fees from Akcea, Imbrium, Janssen, and Pfizer. NR: Consulting fees from Bristol Myers Squibb and Celgene. SAT: Research funding from Celgene, Janssen, Karyopharm, and Sanofi; Consulting fees from Alnylam, Caelum, Celgene, Karyopharm, and Oncopeptides; Speaking fees from Celgene. DS: Consulting fees from Celgene and Janssen. JL: Nothing to disclose. GB: Consulting fees from Pfizer. DK, RS, FD, and FC: Employed by Sanofi. PGR: Grant funding from Bristol Myers Squibb, Celgene, Oncopeptides, and Takeda; Personal fees from Celgene, Janssen, Karyopharm, Oncopeptides, Sanofi, and Takeda.